Background: Intravenous haloperidol can increase the risk for corrected QT interval (QTc) prolongation, torsades de pointes (TdP) and sudden death. There are a number of risk factors reported in the literature for QTc prolongation and TdP with intravenous haloperidol.
Objective: The purpose of this study was to determine the prevalence of baseline risk factors for QTc prolongation and TdP in hospitalized medical inpatients prescribed intravenous haloperidol.
Methods: This is a retrospective cohort study of medically ill hospitalized inpatients prescribed intravenous haloperidol between 30 June 2007 and 1 January 2010. Records were ascertained for the presence of baseline risk factors for QTc prolongation and TdP.
Results: A total of 175 subjects were identified as receiving intravenous haloperidol during the study period. Mean age was 62.9±19.1 years, and 48.6% of subjects were female. At baseline, 85.7% of subjects had ≥1 risk factor for QTc prolongation and TdP, with the majority of these subjects (58.0%) having between two and five risk factors. Of the total study sample, 74.9% had a baseline ECG; mean QTc value was 457 msec (± 40.8 msec). Greater than 50% of subjects had a sex-specific QTc value higher than the increased risk threshold of 450 msec in males or 460 msec in females at baseline. Following intravenous haloperidol administration, 46.9% of subjects had a follow-up ECG obtained within 24 hours. At the time of intravenous haloperidol administration, 93.1% of subjects had a potassium value available and 62.9% had a magnesium value. Approximately 30% of subjects had either a potassium or magnesium value below the normal laboratory range. Of the 175 subjects, 43.4% were taking ≥1 concomitant QTc prolongation medication at the time of intravenous haloperidol administration.
Conclusions: Consistent with previously published reports, patients in this study prescribed intravenous haloperidol had multiple risk factors, both modifiable and non-modifiable, at baseline for QTc prolongation and TdP. The modifiable risk factors may be important targets of interventions aimed at optimizing the safety of the use of intravenous haloperidol, while the non-modifiable risk factors may warrant closer scrutiny with consideration of alternative therapies and continuous monitoring.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists (ASHP), American College of Chest Physicians. Crit Care Med 2002; 30: 119–41
American Psychiatric Association. Practice guidelines for the treatment of patients with delirium. Am J Psychiatry 1999; 156 Suppl. 5: 1–20
Campbell N, Boustani MA, Ayub A, et al. Pharmacological management of delirium in hospitalized adults: a systematic evidence review. J Gen Intern Med 2009; 24: 848–53
Lacasse H, Perreault MM, Williamson DR. Systematic review of antipsychotics for the treatment of hospital-acquired delirium in medically or surgically ill patients. Ann Pharmacother 2006; 40: 1966–73
Rea RS, Battistone S, Fong JJ, et al. Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients. Pharmacotherapy 2007; 27: 588–94
Seitz DP, Gill SS, van Zyl LT. Antipsychotics in the treatment of delirium: a systematic review. J Clin Psychiatry 2007; 68: 11–21
Lonergan E, Britton AM, Luxenberg J. Antipsychotics for delirium. Cochrane Database Syst Rev 2009; (2): CD005594
Schwartz TL, Masand PS. The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 2002; 43: 171–4
Fricchione GL, Nejad SH, Esses JA, et al. Postoperative delirium. Am J Psychiatry 2008; 165: 803–12
US FDA. Information for healthcare professionals: haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). 2007 (this alert highlights revisions to labeling for haloperidol) [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085203.htm: www.fda.gov [Accessed 2011 Sep]
Wilt JL, Minnema AM, Johnson RF, et al. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993; 119: 391–4
Perrault LP, Denault AY, Carrier M, et al. Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting. Can J Anesth 2000; 47: 251–4
Hunt N, Stern TA. The association between intravenous haloperidol and torsades de pointes. Psychosomatics 1995; 36: 541–9
O’Brien JM, Rockwood RP, Suh KI. Haloperidol-induced torsade de pointes. Ann Pharmacother 1999; 33: 1046–50
Kriwisky M, Perry GY, Tarchitsky D, et al. Haloperidol-induced torsades de pointes. Chest 1990; 98: 482–4
Metzger E, Friedman R. Prolongation of the corrected QT and torsade de pointes cardia arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 1993; 13: 128–32
Sharma ND, Rosman HS, Padhi D, et al. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81: 238–40
Hatta K, Takahashi T, Nakamura H, et al. The association between intravenous haloperidol and prolonged QT interval. J Clin Psychopharm 2001; 21: 257–61
Tisdale JE, Padhi ID, Sharma ND, et al. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of torsades de pointes. J Clin Pharmacol 2001; 41: 1310–8
Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?. J Hosp Med 2010; 5: E8–16
Haloperidol [package insert]. Princeton (NJ): Sandoz Inc, 2008 Sep
Titier K, Girodet PO, Verdoux H, et al. Atypical antipsychotics: from potassium channels to torsade pointes and sudden death. Drug Saf 2005; 28: 35–51
Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005; 66 Suppl. 6: 5–10
Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62: 1649–71
Justo D, Prokhorov V, Heller K, et al. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand 2005; 111: 171–6
Vieweg WV, Wood MA, Fernandex A, et al. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 2009; 26: 997–1012
Bazett JC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353–70
Al-Khatib SM, Allan LaPointe NM, Kramer JM, et al. What clinicians should know about the QT interval. JAMA 2003; 289: 2120–7
Vieweg WV. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psych 2003; 5: 205–15
Arizona Cert — Center for Education and Research on Therapeutics [online]. Available from URL: http://www.azcert.org/ [Accessed 2011 Aug 1]
Devlin JW, Bhat S, Roberts RJ, et al. Current perceptions and practices surrounding the recognition and treatment of delirium in the intensive care unit: a survey of 250 critical care pharmacists from eight states. Ann Pharmacother 2011; 45: 1217–29
Desai M, Li L, Desta Z, et al. Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol 2002; 55: 511–7
Blom MT, Bardai A, van Munster BC, et al. Differential changes in QTc duration during in-hospital haloperidol use. PLoS ONE 2011; 6: e23728
Hatta K, Takahashi T, Nakamura H, et al. Hypokalemia and agitation in acute psychotic patients. Psychiatry Res 1999; 86: 85–8
Trojak B, Astruc K, Pinoit JM, et al. Hypokalemia is associated with lengthening of the QT interval in psychiatric patients on admission. Psychiatry Res 2009; 169: 257–60
The authors of this paper have no sources of financial support relevant to this study.
This paper (in part or in whole) has not been previously presented or published.
All authors report no conflicts of interest, including consulting fees, paid expert testimony, employment, grants, honoraria, patents, royalties, stocks or any other relationships or ethical considerations that may involve the subject matter of the manuscript and compromise its integrity.
About this article
Cite this article
Muzyk, A.J., Rayfield, A., Revollo, J.Y. et al. Examination of Baseline Risk Factors for QTc Interval Prolongation in Patients Prescribed Intravenous Haloperidol. Drug Saf 35, 547–553 (2012). https://doi.org/10.2165/11599960-000000000-00000
- Computerize Physician Order Entry
- Medical Inpatient
- Baseline Risk Factor
- Drug Utilization Review